Articles tagged with Target Mrna
A new experimental mRNA vaccine provides protection in preclinical animal models against infection from Borrelia burgdorferi, the bacteria that causes Lyme disease. The vaccine prevents the development of Lyme disease and may represent a powerful tool in reducing Lyme disease cases.
Researchers found a strong positive correlation between BRD4 overexpression and chemoresistance in ovarian cancer. The study demonstrated that BRD4-L and BRD4-S isoforms play a role in promoting chemotherapy resistance in high-grade serous ovarian carcinoma.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers at Children's Hospital of Philadelphia developed TEQUILA-seq, a cost-effective technology for targeted long-read RNA sequencing. This innovation enables accurate accounting of all RNA molecules emanating from a single gene, crucial for understanding diseases like cancer.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
Researchers at the University of Missouri have developed a new method using nanopores to advance discoveries in neuroscience and medical applications. The technique allows for real-time detection of dynamic aptamer-small molecule interactions, which can aid in understanding DNA and RNA diseases and drug discovery.
Research reveals critical role of LINC00901 and its regulatory network in promoting pancreatic cancer progression. A critical axis driving PDAC progression is unveiled through m6A modification.
CHOP and Penn Medicine researchers have developed a proof-of-concept model for delivering gene editing tools directly into diseased blood cells within the body. This approach aims to reduce costs and increase access to gene therapies for blood disorders, which currently require chemotherapy and stem cell transplants.
Researchers at MIT have developed a novel sensor that can detect immune molecule CXCL12, which plays a crucial role in several human diseases including cancer. The device uses receptor proteins found in cell membranes, making it a potential tool for early screening of hard-to-diagnose cancers.
A novel stress signalling system has been discovered by SMART researchers, enabling bacteria cells to adapt and survive against the immune system and certain antibiotics. The breakthrough discovery of RlmN as a stress sensor may lead to the development of new therapies to combat antimicrobial resistance.
Gang Bao's lab receives a 4-year, $2.6 million grant from the National Institutes of Health to investigate the safety and efficacy of using gene editing treatments like CRISPR-Cas9 to treat sickle cell disease. The team aims to understand the mechanisms behind large gene modifications and their biological consequences.
The study identifies 1,074 semi-extractable RNAs potentially involved in phase-separated membraneless organelles. These RNAs are enriched in repressed heterochromatin regions and act as hubs for RNA-RNA interactions.
Researchers at MIT are developing a continuous mRNA manufacturing platform to improve vaccine development and production. The pilot-scale system aims to reduce costs, increase efficiency, and facilitate collaboration in the biopharmaceutical industry.
Researchers at Tel Aviv University have developed a novel approach to fight cancer by inducing cancer cells to produce a toxic protein using mRNA molecules. The treatment was successful in eliminating 44-60% of cancer cells in animal models, with no damage to healthy cells.
Researchers developed a biodegradable nanoparticle that reaches dendritic cells in mice with melanoma and colon cancer, activating an immune response. The nanoparticle improves survival rates for these cancers, with half of mice surviving long-term after treatment.
The study developed multi-valent mRNA vaccines targeting monkeypox enveloped or mature viron surface antigens, inducing dynamic immune responses with robust IgG and neutralizing activities. The vaccines protected a mouse model from lethal VACV challenge.
A new research centre will focus on developing new types of RNA medicine for treating metabolic diseases. The centre, led by Professor Jørgen Kjems at Aarhus University, aims to create targeted treatments for conditions like diabetes and atherosclerosis.
Researchers discovered a protein complex called FERRY that plays a crucial role in transporting messenger RNA in neurons. The study provided evidence of the transport of mRNA using Early Endosomes (EEs) and a novel mode of binding RNA via coiled-coil domains.
Researchers identified mRNAs and long non-coding RNAs targeted by stress granule proteins, which accumulate AD-associated gene transcripts in these structures. SGs may play a key role in regulating AD development through the impairment of protein neurohomeostasis.
Researchers developed a computational platform called IRIS to discover tumor antigens from alternative RNA splicing, expanding cancer immunotherapy targets. Hundreds of predicted TCR targets were found to be presented by human leukocyte antigen molecules.
Researchers developed predictive models to design RNA-binding inhibitors for disease treatment by regulating protein production. The study identified three key features for effective oligonucleotides: thermostability, serum resistance, and RNase H sensitivity.
Scientists are investigating how brain immune cells called microglia change shape in response to hazards using gene transcripts as molecular mediators. The goal is to gain insights into the mechanisms involved and potentially develop new therapies for neurodegenerative diseases.
Scientists have discovered potential broad-spectrum antivirals that target multiple families of RNA viruses, which pose a significant threat to future pandemics. The new agents showed promise in preventing and mitigating viral arthritis caused by Chikungunya virus and rescuing cells from harmful effects of other viruses.
Human ribosomes decode messenger RNA (mRNA) 10 times slower than bacterial ribosomes, but do so more accurately. This slow-down adds accuracy due to human ribosomes being known to be more accurate at translating the code than bacterial ribosomes.
Researchers have developed a new type of nanoparticle that can efficiently deliver CRISPR/Cas9 components to the lungs, allowing for targeted gene editing. In mice studies, the particles delivered mRNA to up to 60% of lung epithelial cells, offering a promising approach to treating genetic diseases such as cystic fibrosis.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers at Texas A&M University have developed the first molecular therapeutic for Angelman syndrome, a devastating neurogenetic disorder. The therapy targets an evolutionarily conserved region in the UBE3A-AS transcript and has shown promising results in clinical trials.
Researchers have designed a new RNA sensor that can selectively activate synthetic genes in specific cells, opening up possibilities for targeted therapies for cancer and other diseases. The system uses an enzyme that naturally exists in most animal cells to detect and repair mismatches in double-stranded RNA.
Gene therapy using CRISPR-Cas9 lipid nanoparticles has been shown to be highly effective in reducing target protein expression in mice. The new delivery system increases the efficiency of in vivo gene therapy, paving the way for safe and effective treatment.
Targeted RNA therapy aims to treat pre-eclampsia by delivering mRNA to placental cells, reducing maternal blood pressure and restoring fetal circulation. The treatment has shown promising results in mice, paving the way for potential treatments for human patients.
A team of researchers led by Ohio University professor Jennifer Hines has uncovered a new class of compounds that can target RNA and disrupt its function. The discovery identified a chemical scaffold that could be used to develop RNA-targeted medicines for various diseases.
A team led by Dr. Feng Wang found that Argonaute 4 binds to and retains snippets of ribonucleic acid molecules guiding the chemical inactivation of genes with matching sequences, playing a crucial role in gene silencing through DNA methylation. The retained RNA fragments help tether AGO4-RNA complexes to corresponding DNA sequences, bo...
A recent study of over 42,000 patients found low adherence to COVID-19 booster dose recommendations among immunocompromised individuals. This vulnerable population faces increased risk of severe COVID-19, underscoring the importance of tailored efforts to ensure they remain up-to-date with booster doses.
Researchers at University of Texas M. D. Anderson Cancer Center develop a novel mRNA delivery system using extracellular vesicles, which can initiate collagen production in cells and has potential for other mRNA therapies
Research finds that individuals who received monoclonal antibodies before COVID vaccination exhibit a diverse antibody response, increasing the coverage provided by vaccines. This phenomenon, known as antibody feedback inhibition, is beneficial for diversifying immune responses to viruses.
Researchers have found that experimental vaccines, including a protein-based vaccine candidate with an adjuvant, provide superior protection against lung disease and higher levels of neutralizing antibodies compared to mRNA vaccines. The results inform the optimization and development of COVID-19 vaccines for young infant populations.
A team from UNIGE has revealed the existence of a hidden 'pocket' on the surface of the non-structural protein Nsp1, which could be used to develop new treatments against Covid-19. This discovery paves the way for innovative therapies targeting the Nsp1 protein and its potential application against other coronaviruses.
Researchers have discovered that targeting a specific mutation in fibrolamellar tumors can reduce tumor growth in mice, offering a promising approach to treating this nearly incurable cancer. The findings highlight the potential for novel therapies against an intractable disease.
Researchers found that SARS-CoV-2 increases methylation of host cell RNA, which can help the virus evade the immune system. This discovery provides insights into how different variants escape immunity and offers potential avenues for novel COVID-19 treatments.
A new CAPSTONE study aims to identify inflammatory biomarkers associated with positive and poor outcomes in patients after intracerebral hemorrhage (ICH) strokes. By analyzing patient blood and plasma samples, researchers hope to develop targeted treatments to prevent long-term brain degeneration.
Researchers have developed an RNA-based editing tool that targets individual cells, enabling precise modification of cell functions to manage diseases. The tool uses the ADAR enzyme to selectively add proteins of interest, offering endless potential applications across the animal kingdom.
Scientists have identified long interspersed nuclear element-1 (L1) RNA as a promising new target for treating progeroid syndromes. Increased L1 RNA expression in cells from patients with these disorders led to deactivation of an enzyme, causing cell aging.
Researchers developed an engineered Cas13 system that detects SARS-CoV-2 in biological samples with high sensitivity and speed. The new platform outperforms traditional PCR testing, finding 10 out of 11 positives and no false positives in clinical samples.
Researchers at McMaster University have discovered a previously unknown bacteria-killing toxin that targets essential RNA molecules in other bacteria. This breakthrough discovery could lead to the development of new antibiotics by exploiting this vulnerability.
A new DNA-based fluorescence technique using single-molecule electron-transfer kinetics can identify point mutations in mRNA, facilitating the diagnosis of gliomas and potentially treating the disease. This breakthrough may lead to real-time cancer diagnostics during surgical biopsies, reducing the need for multiple surgeries.
Researchers at Tufts University have developed a novel mRNA-based approach to generate complex antibodies in muscle cells, which can be used to treat various diseases including botulism and cancer. The technique has shown promising results in neutralizing lethal doses of botulinum neurotoxins in mice.
A study at Tulane University found that recently formed stroke plaques contain messenger RNA that causes inflammation and degrades a protective cap, leading to rupture. This discovery could lead to new tools to stop strokes from happening and develop new drugs or diagnostics to prevent heart attacks and strokes.
Researchers developed a mathematical model to predict the efficiency of nanoparticle delivery into cells, particularly in stem cells. They found that nanoparticles become trapped in bubble-like vesicles, preventing them from reaching their targets.
Researchers at Georgia Institute of Technology have developed a new screening technique called DNA barcoding, which accelerates the discovery of effective lipid nanoparticle carriers. The technique allows for simultaneous testing of many experiments and has improved nanoparticle pre-clinical screening.
Researchers at the University of Houston have made a groundbreaking discovery in repairing and regenerating heart muscle cells in mice. The technology uses synthetic mRNA to deliver mutated transcription factors, which increases the replication of cardiomyocytes. This finding has the potential to become a powerful clinical strategy for...
Researchers at Cold Spring Harbor Laboratory have made a breakthrough in understanding how the RNAi process keeps cells healthy. They discovered that the workhorse protein Argonaute (Ago) uses phosphorylation to break its grip on mRNA targets, allowing it to repress other proteins.
A team of researchers from Kumamoto University has developed a transformable polyrotaxane carrier that can facilitate genome editing using Cas9RNP with high efficiency. The carrier, called amino-PRX, is multi-step transformable and has low cytotoxicity, making it an enormously promising candidate for safe and efficient delivery.
A new CAR T-cell product targeting CLDN6 showed acceptable safety and early signs of efficacy in a phase I/II clinical trial. The therapy combined with an mRNA vaccine expanded transferred CAR T cells and improved tumor cell killing.
A breakthrough discovery has identified a novel approach to tackle metabolic diseases by inhibiting a liver enzyme that regulates appetite and energy expenditure. The treatment, which stabilizes key proteins in the blood, resulted in significant weight loss and improved insulin sensitivity in obese mice.
Researchers at Tel Aviv University developed a drug delivery system based on lipid nanoparticles that utilize RNA to boost personalized cancer care. The nanodrug enhances chemotherapy effectiveness and reinvigorates the immune system, increasing sensitivity to cancer cells.
Researchers have uncovered a collaboration between RNA decay and chromatin regulating complexes that work together to control the levels of transposable element RNAs, preventing genetic instability. The study reveals an unprecedented mechanism of transcriptional and post-transcriptional regulation.
Researchers at Massachusetts General Hospital have discovered a new class of biological factors that can be targeted by small molecule drugs, including noncoding RNAs. This breakthrough could lead to new therapies for genetic disorders such as Rett syndrome and Fragile X syndrome.
Researchers at Temple University found that individuals with prior COVID-19 infection experienced rapid antibody production after the first vaccine dose, but showed little increase after the second dose. This contrasts with those without a history of infection, who exhibited massive responses after the second dose.
Researchers at Colorado State University are developing an RNA-based method for controlling herbicide-resistant weeds using gene-silencing technology. The goal is to create a non-genetically modified, shelf-stable spray that targets specific strands of RNA in weed cells, leaving crops untouched.